Yeast strains producing mammalian-like complex N-glycans
Described herein are methods and genetically engineered fungal cells useful for producing target molecules containing mammalian-like complex N-glycans or containing intermediates in a mammalian glycosylation pathway.
1. A substantially pure culture of Yarrowia lipolytica cells, a substantial number of which are genetically engineered to produce glycoproteins comprising GalGlcNAc 2 Man 3 GlcNAc 2 or Gal 2 GlcNAc 2 Man 3 GlcNAc 2 N-glycans, wherein said cells are genetically engineered to be deficient in Outer CHain elongation (OCH1) activity and in Asparagine Linked Glycosylation 3 (ALG3) activity and to comprise one or more nucleic acids encoding an α-1,2-mannosidase, a nucleic acid encoding Asparagine Linked Glycosylation 6 (ALG6), and one or more nucleic acids encoding each of a GlcNAc-transferase I, a GlcNAc-transferase II, and a galactosyltransferase, wherein each of said one or more nucleic acids encoding said α-1,2-mannosidase, said GlcNAc-transferase I, said GlcNAc-transferase II, and said galactosyltransferase comprises nucleotide sequences encoding targeting sequences to target each encoded protein to an intracellular compartment, wherein said cells produce proteins comprising GalGlcNAc 2 Man 3 GlcNAc 2 or Gal 2 GlcNAc 2 Man 3 GlcNAc 2 N-glycans.
2. The culture of claim 1 , wherein each of said cells further comprises a nucleic acid encoding a target protein, wherein each of said cells produces said target protein comprising GalGlcNAc 2 Man 3 GlcNAc 2 or Gal 2 GlcNAc 2 Man 3 GlcNAc 2 N-glycans.
3. The culture of claim 2 , wherein the target protein is a protein selected from the group consisting of a therapeutic glycoprotein, an antibody or fragment thereof, interferon-β, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-γ, and erythropoietin.
4. The culture of claim 2 , wherein said target protein is an antibody or fragment thereof comprising an Fc part that can interact with an Fc receptor.
5. The culture of claim 1 , wherein said intracellular compartment is the Golgi apparatus.
6. The culture of claim 1 , wherein said coding sequence encoding said α-1,2-mannosidase comprises an endoplasmic reticulum targeting sequence to target the encoded α-1,2-mannosidase to the endoplasmic reticulum.
7. The culture of claim 6 , wherein said endoplasmic reticulum targeting sequence is an HDEL endoplasmic reticulum-retention (HDEL) sequence (SEQ ID NO: 21).
8. The culture of claim 1 , wherein each of said cells further comprise a nucleic acid encoding the α and β subunits of a Glucosidase II.
9. An isolated Yarrowia lipolytica cell genetically engineered to produce proteins comprising GalGlcNAc 2 Man 3 GlcNAc 2 or Gal 2 GlcNAc 2 Man 3 GlcNAc 2 N-glycans, wherein said cell is genetically engineered to be deficient in Outer CHain elongation (OCH1) activity and in Asparagine Linked Glycosylation 3 (ALG3) activity and to comprise one or more nucleic acids encoding an α-1,2-mannosidase, a nucleic acid encoding Asparagine Linked Glycosylation 6 (ALG6), and one or more nucleic acids encoding each of a GlcNAc-transferase I, a GlcNAc-transferase II, and a galactosyltransferase, wherein each of said one or more nucleic acids encoding said α-1,2-mannosidase, said GlcNAc-transferase I, said GlcNAc-transferase II, and said galactosyltransferase comprises nucleotide sequences encoding targeting sequences to target each encoded protein to an intracellular compartment, wherein said cell produces proteins comprising GalGlcNAc 2 Man 3 GlcNAc 2 or Gal 2 GlcNAc 2 Man 3 GlcNAc 2 N-glycans.
10. The Yarrowia lipolytica cell of claim 9 , wherein said cell further comprises a nucleic acid encoding a target protein, wherein each of said cells produces said target protein comprising GalGlcNAc2Man3GlcNAc2 or Gal2GlcNAc2Man3GlcNAc2 N-glycans.
11. The Yarrowia lipolytica cell of claim 10 , wherein the target protein is a protein selected from the group consisting of a therapeutic glycoprotein, an antibody or fragment thereof, interferon-β, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-γ, and erythropoietin.
12. The Yarrowia lipolytica cell of claim 10 , wherein said target protein is an antibody or fragment thereof comprising an Fc part that can interact with an Fc receptor.
13. The Yarrowia lipolytica cell of claim 9 , wherein said intracellular compartment is the Golgi apparatus.
14. The Yarrowia lipolytica cell of claim 9 , wherein said coding sequence encoding said α-1,2-mannosidase is linked to an endoplasmic reticulum targeting sequence to target the encoded α-1,2-mannosidase to the endoplasmic reticulum.
15. The Yarrowia lipolytica cell of claim 14 , wherein said endoplasmic reticulum targeting sequence is an HDEL endoplasmic reticulum-retention (HDEL) sequence (SEQ ID NO: 21).
16. The Yarrowia lipolytica cell of claim 9 , wherein said cell further comprises a nucleic acid encoding the α and β subunits of a Glucosidase II.